Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression

Sooryanarayana Varambally, Jianjun Yu, Bharathi Laxman, Daniel R. Rhodes, Rohit Mehra, Scott A. Tomlins, Rajal B. Shah, Uma Chandran, Federico A. Monzon, Michael J. Becich, John T. Wei, Kenneth J. Pienta, Debashis Ghosh, Mark A. Rubin, Arul M. Chinnaiyan

Research output: Contribution to journalArticle

540 Citations (Scopus)

Abstract

Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis of proteomic alterations during cancer progression has been a more daunting task. Here, we employed high-throughput immunoblotting in order to interrogate tissue extracts derived from prostate cancer. We identified 64 proteins that were altered in prostate cancer relative to benign prostate and 156 additional proteins that were altered in metastatic disease. An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed, revealing only 48%-64% concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors.

Original languageEnglish (US)
Pages (from-to)393-406
Number of pages14
JournalCancer Cell
Volume8
Issue number5
DOIs
StatePublished - Nov 1 2005
Externally publishedYes

Fingerprint

Proteomics
Prostatic Neoplasms
Neoplasms
Proteins
Tissue Extracts
Immunoblotting
Prostate
Genes

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., ... Chinnaiyan, A. M. (2005). Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 8(5), 393-406. https://doi.org/10.1016/j.ccr.2005.10.001

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. / Varambally, Sooryanarayana; Yu, Jianjun; Laxman, Bharathi; Rhodes, Daniel R.; Mehra, Rohit; Tomlins, Scott A.; Shah, Rajal B.; Chandran, Uma; Monzon, Federico A.; Becich, Michael J.; Wei, John T.; Pienta, Kenneth J.; Ghosh, Debashis; Rubin, Mark A.; Chinnaiyan, Arul M.

In: Cancer Cell, Vol. 8, No. 5, 01.11.2005, p. 393-406.

Research output: Contribution to journalArticle

Varambally, S, Yu, J, Laxman, B, Rhodes, DR, Mehra, R, Tomlins, SA, Shah, RB, Chandran, U, Monzon, FA, Becich, MJ, Wei, JT, Pienta, KJ, Ghosh, D, Rubin, MA & Chinnaiyan, AM 2005, 'Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression', Cancer Cell, vol. 8, no. 5, pp. 393-406. https://doi.org/10.1016/j.ccr.2005.10.001
Varambally, Sooryanarayana ; Yu, Jianjun ; Laxman, Bharathi ; Rhodes, Daniel R. ; Mehra, Rohit ; Tomlins, Scott A. ; Shah, Rajal B. ; Chandran, Uma ; Monzon, Federico A. ; Becich, Michael J. ; Wei, John T. ; Pienta, Kenneth J. ; Ghosh, Debashis ; Rubin, Mark A. ; Chinnaiyan, Arul M. / Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. In: Cancer Cell. 2005 ; Vol. 8, No. 5. pp. 393-406.
@article{b5a7544b8bd445de9514c89982988769,
title = "Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression",
abstract = "Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis of proteomic alterations during cancer progression has been a more daunting task. Here, we employed high-throughput immunoblotting in order to interrogate tissue extracts derived from prostate cancer. We identified 64 proteins that were altered in prostate cancer relative to benign prostate and 156 additional proteins that were altered in metastatic disease. An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed, revealing only 48{\%}-64{\%} concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors.",
author = "Sooryanarayana Varambally and Jianjun Yu and Bharathi Laxman and Rhodes, {Daniel R.} and Rohit Mehra and Tomlins, {Scott A.} and Shah, {Rajal B.} and Uma Chandran and Monzon, {Federico A.} and Becich, {Michael J.} and Wei, {John T.} and Pienta, {Kenneth J.} and Debashis Ghosh and Rubin, {Mark A.} and Chinnaiyan, {Arul M.}",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.ccr.2005.10.001",
language = "English (US)",
volume = "8",
pages = "393--406",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression

AU - Varambally, Sooryanarayana

AU - Yu, Jianjun

AU - Laxman, Bharathi

AU - Rhodes, Daniel R.

AU - Mehra, Rohit

AU - Tomlins, Scott A.

AU - Shah, Rajal B.

AU - Chandran, Uma

AU - Monzon, Federico A.

AU - Becich, Michael J.

AU - Wei, John T.

AU - Pienta, Kenneth J.

AU - Ghosh, Debashis

AU - Rubin, Mark A.

AU - Chinnaiyan, Arul M.

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis of proteomic alterations during cancer progression has been a more daunting task. Here, we employed high-throughput immunoblotting in order to interrogate tissue extracts derived from prostate cancer. We identified 64 proteins that were altered in prostate cancer relative to benign prostate and 156 additional proteins that were altered in metastatic disease. An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed, revealing only 48%-64% concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors.

AB - Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis of proteomic alterations during cancer progression has been a more daunting task. Here, we employed high-throughput immunoblotting in order to interrogate tissue extracts derived from prostate cancer. We identified 64 proteins that were altered in prostate cancer relative to benign prostate and 156 additional proteins that were altered in metastatic disease. An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed, revealing only 48%-64% concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=27644506613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644506613&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2005.10.001

DO - 10.1016/j.ccr.2005.10.001

M3 - Article

C2 - 16286247

AN - SCOPUS:27644506613

VL - 8

SP - 393

EP - 406

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 5

ER -